Brief ReportEpidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study
Key Words
Cited by (0)
The study was designed by the members of the Steering committee: TC, PB, RD, WO, HP, PB, LD, ZZ and RP All authors contributed to the acquisition and interpretation of data. The manuscript was prepared by PB, ZZ and RP, and its final version was approved by all authors.
Disclosure: Dr. Robert Pirker received speaker's fee and honoraria for advisory boards from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, Pfizer, Roche, and Synta. Dr. Tanja Cufer received honoraria for advisory boards from Boehringer Ingelheim and Pfizer. Dr. Rodryg Ramlau has received honoraria for advisory boards from Boehringer Ingelheim, Eli Lilly, and MSD. All other authors declare no conflict of interest.
This study was supported by an unrestricted grant from Boehringer Ingelheim RCV, Vienna, Austria.